Zhangjie Su1, Federico Roncaroli2, Pascal F Durrenberger2, David J Coope3, Konstantina Karabatsou4, Rainer Hinz1, Gerard Thompson1, Federico E Turkheimer5, Karolina Janczar2, Daniel Du Plessis6, Andrew Brodbelt7, Alan Jackson1, Alexander Gerhard1, Karl Herholz8. 1. Wolfson Molecular Imaging Center, University of Manchester, Manchester, United Kingdom. 2. Division of Brain Science, Imperial College London, London, United Kingdom. 3. Wolfson Molecular Imaging Center, University of Manchester, Manchester, United Kingdom Department of Neurosurgery, Salford Royal NHS Foundation Trust, Salford, United Kingdom. 4. Department of Neurosurgery, Salford Royal NHS Foundation Trust, Salford, United Kingdom. 5. Center for Neuroimaging, Institute of Psychiatry, King's College London, London, United Kingdom. 6. Neuropathology Unit, Salford Royal NHS Foundation Trust, Salford, United Kingdom; and. 7. Department of Neurosurgery, The Walton Center NHS Foundation Trust, Liverpool, United Kingdom. 8. Wolfson Molecular Imaging Center, University of Manchester, Manchester, United Kingdom karl.herholz@manchester.ac.uk.
Abstract
UNLABELLED: The 18-kDa mitochondrial translocator protein (TSPO) is upregulated in high-grade astrocytomas and can be imaged by PET using the selective radiotracer (11)C-(R)PK11195. We investigated (11)C-(R)PK11195 binding in human gliomas and its relationship with TSPO expression in tumor tissue and glioma-associated microglia/macrophages (GAMs) within the tumors. METHODS: Twenty-two glioma patients underwent dynamic (11)C-(R)PK11195 PET scans and perfusion MR imaging acquisition. Parametric maps of (11)C-(R)PK11195 binding potential (BPND) were generated. Coregistered MR/PET images were used to guide tumor biopsy. The tumor tissue was quantitatively assessed for TSPO expression and infiltration of GAMs using immunohistochemistry and double immunofluorescence. The imaging and histopathologic parameters were compared among different histotypes and grades and correlated with each other. RESULTS: BPND of (11)C-(R)PK11195 in high-grade gliomas was significantly higher than in low-grade astrocytomas and low-grade oligodendrogliomas. TSPO in gliomas was expressed predominantly by neoplastic cells, and its expression correlated positively with BPND in the tumors. GAMs only partially contributed to the overall TSPO expression within the tumors, and TSPO expression in GAMs did not correlate with tumor BPND. CONCLUSION: PET with (11)C-(R)PK11195 in human gliomas predominantly reflects TSPO expression in tumor cells. It therefore has the potential to effectively stratify patients who are suitable for TSPO-targeted treatment.
UNLABELLED: The 18-kDa mitochondrial translocator protein (TSPO) is upregulated in high-grade astrocytomas and can be imaged by PET using the selective radiotracer (11)C-(R)PK11195. We investigated (11)C-(R)PK11195 binding in human gliomas and its relationship with TSPO expression in tumor tissue and glioma-associated microglia/macrophages (GAMs) within the tumors. METHODS: Twenty-two glioma patients underwent dynamic (11)C-(R)PK11195 PET scans and perfusion MR imaging acquisition. Parametric maps of (11)C-(R)PK11195 binding potential (BPND) were generated. Coregistered MR/PET images were used to guide tumor biopsy. The tumor tissue was quantitatively assessed for TSPO expression and infiltration of GAMs using immunohistochemistry and double immunofluorescence. The imaging and histopathologic parameters were compared among different histotypes and grades and correlated with each other. RESULTS: BPND of (11)C-(R)PK11195 in high-grade gliomas was significantly higher than in low-grade astrocytomas and low-grade oligodendrogliomas. TSPO in gliomas was expressed predominantly by neoplastic cells, and its expression correlated positively with BPND in the tumors. GAMs only partially contributed to the overall TSPO expression within the tumors, and TSPO expression in GAMs did not correlate with tumor BPND. CONCLUSION: PET with (11)C-(R)PK11195 in human gliomas predominantly reflects TSPO expression in tumor cells. It therefore has the potential to effectively stratify patients who are suitable for TSPO-targeted treatment.
Authors: Satish K Chitneni; Zachary J Reitman; David M Gooden; Hai Yan; Michael R Zalutsky Journal: Eur J Med Chem Date: 2016-04-28 Impact factor: 6.514
Authors: S E Holmes; R Hinz; R J Drake; C J Gregory; S Conen; J C Matthews; J M Anton-Rodriguez; A Gerhard; P S Talbot Journal: Mol Psychiatry Date: 2016-10-04 Impact factor: 15.992
Authors: William C Kreisl; Robin Lawrence; Emily Page; Andrew F Teich; Deepa S Subramaniam; Robert B Innis; R Scott Turner Journal: Neurology Date: 2017-02-08 Impact factor: 9.910
Authors: M Unterrainer; D F Fleischmann; F Vettermann; V Ruf; L Kaiser; D Nelwan; S Lindner; M Brendel; V Wenter; S Stöcklein; J Herms; V M Milenkovic; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; N L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-05 Impact factor: 9.236
Authors: Nathalie L Albert; M Unterrainer; D F Fleischmann; S Lindner; F Vettermann; A Brunegraf; L Vomacka; M Brendel; V Wenter; C Wetzel; R Rupprecht; J-C Tonn; C Belka; P Bartenstein; M Niyazi Journal: Eur J Nucl Med Mol Imaging Date: 2017-08-19 Impact factor: 9.236
Authors: Bastian Zinnhardt; Michael Müther; Wolfgang Roll; Philipp Backhaus; Astrid Jeibmann; Claudia Foray; Cristina Barca; Christian Döring; Bertrand Tavitian; Frédéric Dollé; Matthias Weckesser; Alexandra Winkeler; Sven Hermann; Stefan Wagner; Heinz Wiendl; Walter Stummer; Andreas H Jacobs; Michael Schäfers; Oliver M Grauer Journal: Neuro Oncol Date: 2020-07-07 Impact factor: 12.300